Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance
2003; Elsevier BV; Volume: 101; Issue: 7 Linguagem: Inglês
10.1182/blood-2002-04-1055
ISSN1528-0020
AutoresAndreas Greinacher, Petra Eichler, Dorothea Albrecht, Ulrike Strobel, Bernd Pötzsch, Bengt I. Eriksson,
Tópico(s)Intramuscular injections and effects
ResumoRecombinant hirudin has been found to be immunogenic in patients treated with lepirudin following heparin-induced thrombocytopenia (HIT). We assessed the incidence of immunoglobulin G (IgG) antihirudin antibodies by enzyme-linked immunosorbent assay in 112 patients enrolled in a dose-finding study with desirudin. Patients received desirudin subcutaneously following orthopedic hip surgery at 10 mg twice a day (n = 17), 15 mg twice a day (n = 75), and 20 mg twice a day (n = 20). Of 112 patients, 11 (9.8%) developed antihirudin antibodies independently of the dose. The rate of immunization did not differ from that observed in HIT patients treated with lepirudin (P = .113). Plasma concentrations of desirudin did not differ between antihirudin antibody–positive and –negative patients. Antihirudin antibodies had no impact on incidences of deep vein thrombosis and/or pulmonary embolism, allergic reactions, and hemorrhage. However, the total number of immunized patients observed was low and so infrequent (but severe) effects of antihirudin antibodies cannot be excluded.
Referência(s)